Bernard A. Fox, Co- founder, President, and CEO of UbiVac, shared Patrick Hwu’s, President and CEO at Moffitt Cancer Center, shared a post on LinkedIn:
“Last week was a Cancer’s Dark Matter week.
Between Saturday night, May 30, and Friday night, June 5, I had the opportunity to deliver three presentations highlighting the first ‘Dark Matter’ cancer immunotherapy to reach the clinic.
UbiVac’s DPV001 is an off-the-shelf immunotherapy designed to treat a broad range of solid tumors, including Breast Cancer, Prostate Cancer, Colon Cancer, Lung Cancer, Head and Neck Cancer, Ovarian Cancer, GBM, Pancreatic Cancer, and others.
Our data demonstrate that DPV-001 can prime T-cell responses in vivo against cryptic Dark Matter antigens expressed by cancer cells. In patients with recurrent/metastatic HNSCC, treatment with DPV-001 combined with checkpoint blockade has generated encouraging clinical activity, including response rates approximately three times higher than historically observed with anti-PD-1 therapy alone.
After decades of focusing almost exclusively on mutations and neoantigens, the field is increasingly recognizing the therapeutic potential of the vast ‘dark genome’ as a source of shared cancer antigens. It is exciting to see these concepts move from discovery to patients and begin demonstrating clinical impact.
The 3 presentations were:
1) CAHON Symposium at ASCO 2026 (Chicago)
2) National Cancer Institute (NCI) Director’s Cancer Vaccines Initiative – Subcommittee 1
3) 3rd WIC-Asia Asia-Pacific Tumor Immunotherapy Forum (Shanghai, China)
Tomorrow I will start the week with a presentation at Fudan University.”
More posts featuring Bernard A. Fox.
